| Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients. |
|
Sook Jung Yun, Jee Bum Lee, Kyu Sik Kim, Young Chul Kim |
1Department of Dermatology, Chonnam National University Hwasun Hospital, Korea.
2Department of Internal Medicine, Chonnam National University Hwasun Hospital, Korea. kyc0923@jnu.ac.kr |
|
|
| Abstract |
BACKGROUND
Gefitinib (ZD 1839, Iressa) is a new anticancer agent; more specifically, it is a selective epidermal growth factor receptor tyrosine kinase inhibitor that is, widely used for various solid cancers, including lung cancer. Cutaneous adverse reactions induced by gefitinib have recently been reported; however, not much on this topic has been reported in the Korean literature. METHOD: We studied cutaneous adverse reactions of gefitinib in 23 patients who suffered with non-small cell lung cancer at Chonnam National University Hwasun Hospital from October 2004 to September 2005. RESULT: The patients ranged from 23-72 years old, and there were 17 patients with adenocarcinoma, 5 with squamous cell carcinoma and 1 with bronchioloalveolar carcinoma. The most common adverse reaction was acneiform eruptions in 15 patients (65.2%). This reaction appeared within 2 months after medication, and it didn't correlate with the therapeutic response and tumor type. Pruritus was the second most common reaction (39.1%), which was mild and generalized, especially around eyelid area. Xerosis (26.1%), exfoliation on palm and sole (21.7%), and paronychia (21.7%) followed. Hair breakage and intertrigo were rare adverse reactions. CONCLUSION: Various cutaneous adverse reactions were observed in patients with non-small cell lung carcinoma after gefitinib treatment. The skin complications could be alleviated with dermatologic consultations and treatments, skin complications could be alleviated. |
| Key Words:
Gefitinib, Cutaneous adverse reactions, Lung cancer |
|
PDF Links
Full text via DOI
Download Citation
